1. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res 2008;195:198-213. PMID:
18571247
3. Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993;45:253-308. PMID:
8248281
5. Klarskov P, Hørby-Petersen J. Influence of serotonin on lower urinary tract smooth muscle in vitro. Br J Urol 1986;58:507-13. PMID:
3779352
8. D’Agostino G, Condino AM, Gallinari P, Franceschetti GP, Tonini M. Characterization of prejunctional serotonin receptors modulating [3H]acetylcholine release in the human detrusor. J Pharmacol Exp Ther 2006;316:129-35. PMID:
16166271
9. Imamura T, Ishizuka O, Ogawa T, Minagawa T, Ishikawa M, Hiragata S, et al. Expression of 5-hydroxytryptamine receptors in human urinary bladders with benign prostatic hyperplasia. Adv Ther 2015;32 Suppl 1:29-37. PMID:
26391373
10. Baxter G, Kennett G, Blaney F, Blackburn T. 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci 1995;16:105-10. PMID:
7792930
11. Ismaiel AM, Arruda K, Teitler M, Glennon RA. Ketanserin analogues: the effect of structural modification on 5-HT2 serotonin receptor binding. J Med Chem 1995;38:1196-202. PMID:
7707322
12. Sakai T, Kasahara K, Tomita K, Ikegaki I, Kuriyama H. Naftopidil inhibits 5-hydroxytryptamine-induced bladder contraction in rats. Eur J Pharmacol 2013;700:194-200. PMID:
23274492
13. Hørby-Petersen J, Schmidt PF, Meyhoff HH, Frimodt-Møller C, Mathiesen FR. The effects of a new serotonin receptor antagonist (ketanserin) on lower urinary tract function in patients with prostatism. J Urol 1985;133:1094-8. PMID:
2582152
14. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H, et al. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 2005;96:581-6. PMID:
16104914
16. Reimann IW, Okonkwo PO, Klotz U. Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol 1983;25:73-6. PMID:
6617728
17. de Groat WC, Yoshiyama M, Ramage AG, Yamamoto T, Somogyi GT. Modulation of voiding and storage reflexes by activation of alpha1-adrenoceptors. Eur Urol 1999;36 Suppl 1:68-73. PMID:
10393477
19. Ismaiel AM, Titeler M, Miller KJ, Smith TS, Glennon RA. 5-HT1 and 5-HT2 binding profiles of the serotonergic agents alpha-methylserotonin and 2-methylserotonin. J Med Chem 1990;33:755-8. PMID:
2299641
20. Feldman PD. Effects of serotonin-1 and serotonin-2 receptor agonists on neuronal activity in the nucleus tractus solitarius. J Auton Nerv Syst 1995;56:119-24. PMID:
8786274
21. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994;46:157-203. PMID:
7938165
22. Campos-Bedolla P, Vargas MH, Calixto E, Segura P, Mendoza-Patiño N, Figueroa A, et al. Alpha-methyl-5-HT, a 5-HT2 receptor agonist, stimulates beta2-adrenoceptors in guinea pig airway smooth muscle. Pharmacol Res 2006;54:468-73. PMID:
17079161
23. Hoyer D, Vos P, Closse A, Pazos A, Palacios JM, Davies H. [3H] ketanserin labels 5-HT2 receptors and alpha 1-adrenoceptors in human and pig brain membranes. Naunyn Schmiedebergs Arch Pharmacol 1987;335:226-30. PMID:
2884572
24. Sorbi C, Franchini S, Tait A, Prandi A, Gallesi R, Angeli P, et al. 1,3-Dioxolane-based ligands as rigid analogues of naftopidil: structure-affinity/activity relationships at alpha1 and 5-HT1A receptors. ChemMedChem 2009;4:393-9. PMID:
19152363
25. Israilova M, Suzuki F, Tanaka T, Nagatomo T, Taniguchi T, Muramatsu I. Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes. Pharmacology 2002;65:69-73. PMID:
11937776
26. Sathi ZS, Anisuzzaman AS, Morishima S, Suzuki F, Tanaka T, Yoshiki H, et al. Different affinities of native alpha1B-adrenoceptors for ketanserin between intact tissue segments and membrane preparations. Eur J Pharmacol 2008;584:222-8. PMID:
18336813
27. Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol 1999;79:447-54. PMID:
10361884
28. Borbe HO, Metzenauer P, Szelenyi I. 5-HT1A-agonistic properties of naftopidil, a novel antihypertensive drug. Eur J Pharmacol 1991;205:105-7. PMID:
1839829
29. Sarrouilhe D, Clarhaut J, Defamie N, Mesnil M. Serotonin and cancer: what is the link? Curr Mol Med 2015;15:62-77. PMID:
25601469
30. Siddiqui EJ, Shabbir MA, Mikhailidis DP, Mumtaz FH, Thompson CS. The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int 2006;97:634-9. PMID:
16469039
31. Jungwirth N, Haeberle L, Schrott KM, Wullich B, Krause FS. Serotonin used as prognostic marker of urological tumors. World J Urol 2008;26:499-504. PMID:
18581119
32. Moreau M, Lestage J, Verrier D, Mormede C, Kelley KW, Dantzer R, et al. Bacille Calmette-Guérin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. J Infect Dis 2005;192:537-44. PMID:
15995970
34. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:702-21. PMID:
21185346